AzTrials
AzTrials

AmblyopiaNCT07764198

A Randomized Controlled Trial of Gabor-Based Perceptual Learning for Adult Amblyopia

A study testing Gabor training in people with Amblyopia and Anisometropia, run by Jiannan Huang at 1 site in China.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This study is initiated and conducted by the Shanghai Eye Disease Prevention and Treatment Center / Shanghai Eye Hospital. Many people once believed that amblyopia (commonly known as "lazy eye") could only be treated during childhood (the critical period of visual development) and that nothing could be done once we… Read more about this study

Who is it for?
Ages 18 to 39 years
Conditions the study is for
Amblyopia, Anisometropia
What is being tested?
Gabor training
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
80 participants
Where
1 siteChina
Study dates
25 May 2025to Dec 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 39 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Written informed consent; age 18-39 years inclusive at randomization.
  • Diagnosis of amblyopia, with amblyopic-eye BCVA of approximately 20-70 ETDRS letters (approximately decimal BCVA 0.05-0.6).
  • Amblyopia caused by anisometropia, strabismus, or both, meeting the following definitions:
  • Anisometropic amblyopia: interocular spherical-equivalent difference ≥1.00 D or astigmatic difference ≥1.50 D in any meridian, with no manifest strabismus at distance or near.
  • Strabismic amblyopia: strabismus at distance or near, or a history of strabismus surgery, without meeting the anisometropia criterion.
  • Combined-mechanism amblyopia: meeting both the strabismus and anisometropia criteria.
  • Completion of standardized optical correction and the 8-12-week stability period; absolute difference between week -4 and week 0 ETDRS scores <5 letters, with no continuing pretreatment improvement trend.
  • Ability to use the study device for home training and accept electronic adherence monitoring.

Who cannot join

  • Eccentric fixation, clinically significant nystagmus, or inability to complete reliable ETDRS testing.
  • Corneal, lenticular, retinal, macular, optic-nerve, or neurologic disease capable of explaining the visual-acuity reduction.
  • Study-eye spherical equivalent <-8.00 D, or high refractive error judged by the investigator to compromise test reliability.
  • Recent intraocular surgery or ocular trauma, or extraocular-muscle surgery considered likely to affect outcomes.
  • Diplopia at baseline that interferes with safety evaluation, or an unacceptable training risk as judged by the investigator.
  • Patching, penalization, other visual training, or treatment likely to affect amblyopia outcomes within the prespecified period before randomization.
  • Inability to complete follow-up, understand the tasks, or participation in another clinical study likely to affect outcomes.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

China1 site, 1 recruiting
  • Shanghai Eye Disease Prevention and Treatment Center

    Shanghai

    Yan Xu, (021)62982727-856, drxuyan_2004@163.com

    Recruiting

Other trials in China

About this study

This study is initiated and conducted by the Shanghai Eye Disease Prevention and Treatment Center / Shanghai Eye Hospital. Many people once believed that amblyopia (commonly known as "lazy eye") could only be treated during childhood (the critical period of visual development) and that nothing could be done once we reached adulthood. However, modern visual science research has revealed that the adult visual cortex still retains a certain degree of "neuroplasticity" (the brain's ability to reorganize, learn, and adapt). The Gabor target training used in this study-powered by RevitalVision software-is a scientifically proven visual training program. By repeatedly performing visual tasks near your perception threshold on a computer screen, this training exercises your eye-brain coordination, helping your brain process visual information much more efficiently.

To help you and your family participate with peace of mind, we have compiled the following answers to frequently asked questions:

Read more

Q1: How will I participate in this study? What is the difference between the two groups?

To scientifically compare the training's effectiveness, this study uses a rigorous randomized controlled design. A total of 80 eligible participants will be randomly assigned by a computer program in a 1:1 ratio to one of two groups:

Immediate Training Group:

You will begin the 12-week home-based Gabor visual training right after randomization. Your study participation ends after your Week 12 follow-up.

Delayed Training Group:

During the first 12 weeks after randomization, you will simply wear your prescribed glasses and go about your daily life without active visual training.

After completing your Week 12 eye evaluation, you will receive the exact same 12-week Gabor visual training for free (conducted from Week 12 to Week 24).

Please be assured: No matter which group you are assigned to, every eligible participant will ultimately receive the exact same 12-week professional visual training. This "delayed treatment" design is highly ethical. It ensures everyone gets treated while allowing us to compare the two groups transitionally during the first 12 weeks, thereby ruling out other factors like "getting used to the vision charts" or "gradually adjusting to new glasses".

Q2: How is the visual training performed? Is it difficult to do at home?

The training is fully home-based, meaning you do not need to visit the hospital constantly. However, it requires your dedication and, ideally, supervision from your family:

Training Tools: You will use the specialized RevitalVision perceptual learning software on a calibrated computer monitor.

Training Environment: The training should be done in a dark or standard low-light room. Your only main light source should be the computer screen, and you will sit exactly 1.5 meters away.

Glasses \& Patching: You must wear your prescribed study glasses during training. If you have monocular (one-sided) amblyopia, you will need to patch your stronger eye (non-study eye), using only your weaker eye (amblyopia eye) to view the screen.

Frequency \& Duration: You will train 4 times a week, for about 30 minutes per session, over a continuous span of 12 weeks. The software is adaptive: it automatically adjusts the difficulty of your next session based on your performance to keep you at your optimal training zone.

Q3: What do I need to do at the hospital during the study?

Your safety and visual health are our top priorities. We will provide meticulous, standardized eye examinations throughout the study:

Before the training begins, you will go through an 8- to 12-week "Refractive Stability Phase". During this time, we will perform cycloplegic refraction (dilation) and prescribe your glasses, checking your vision multiple times to ensure your baseline sight is completely stable.

During the study, you will only need to visit the clinic for follow-ups at Weeks 6 and 12 (the Delayed Group will also have visits at Weeks 18 and 24).

At these visits, our examiners (who do not know which group you are in to ensure objectivity) will measure your vision using standard ETDRS charts, evaluate your contrast sensitivity (using the computerized FrACT test), assess your stereoacuity (3D vision), and capture advanced 3D structural scans of your retina and choroid using Swept-Source OCT.

Q4: Is the training safe? What if my vision gets worse? The visual training is entirely physical and non-invasive, with an excellent safety record.

In very rare cases, some participants might experience mild, temporary eye strain, headaches, or slight discomfort when they first start training.

Double-Safety \& Rescue Protocols: We have set strict "rescue criteria". If at any point during your observation or training, your vision drops significantly or if you experience persistent double vision, we will immediately initiate a professional assessment. If necessary, we will halt the training and provide standard clinical medical care.

Being tested
Gabor training
Medical subject headings
Amblyopia, Anisometropia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Gabor trainingDevice

    Gabor-Based Perceptual Learning:

    Home-based training will use the RevitalVision visual perceptual-learning software. Training should be conducted in a dark or standardized low-illumination environment, with a calibrated computer display as the primary light source and a viewing distance of 1.5 m. Training modes include single-image, clarity, lateral-masking, and image-shift tasks, with parameters adaptively adjusted according to performance.

Study groups in NCT07764198
Study groupRoleWhat they receive
Immediate-Training GroupActive comparatorNot described
Receives: Device: Gabor training
Delayed-Training GroupOtherDelayed-Training Group: Gabor-Based Perceptual Learning Home-based training will be delayed by 12 weeks.
Receives: Device: Gabor training

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in amblyopic-eye ETDRS letters

    Measured: Change from randomized baseline in amblyopic-eye ETDRS letters at week 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Aug 2026
  2. Study start25 May 2025
  3. Primary completionOct 2026 (estimated)
  4. Study completionDec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
80 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07764198
Sponsor's protocol ID
20250325.2.1
Status last verified
Aug 2026
First submitted
9 Aug 2026
Last updated
13 Aug 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Gabor training in people with Amblyopia and Anisometropia, run by Jiannan Huang at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 13 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Yan Xu (021-62982727-856, drxuyan_2004@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in amblyopic-eye ETDRS letters (time frame: Change from randomized baseline in amblyopic-eye ETDRS letters at week 12). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2026; AzTrials last refreshed its copy on 30 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in